Table 2.
Cox proportional hazards models describing predictors of overall survival duration after COVID-19 testing
| Characteristic | Hazard ratio (95% CI) | P value |
|---|---|---|
| Sex | ||
| Male | [reference] | 0.037 |
| Female | 2.48 (1.06-5.81) | |
| Age, per y | 1.01 (0.98-1.05) | 0.370 |
| Ethnicity | ||
| Non-Hispanic/other/unknown | [reference] | - |
| Hispanic | 0.66 (0.26-1.66) | 0.374 |
| Primary cancer site | ||
| Breast | [reference] | - |
| Prostate | 0.13 (0.02-1.10) | 0.061 |
| Lung | 3.18 (1.09-9.27)∗ | 0.034∗ |
| Other | 1.07 (0.38-3.01) | 0.900 |
| Interval from last RT to COVID-19 testing | ||
| <1 mo | 0.40 (0.05-3.22) | 0.386 |
| 1 mo to 1 y | 2.96 (1.03-8.51)∗ | 0.044∗ |
| 1-5 y | 1.52 (0.57-4.09) | 0.405 |
| > 5 y | [reference] | - |
| Mean lung radiation therapy dose, per Gy | 1.12 (1.04-1.20)∗ | 0.002∗ |
| Mean lung radiation therapy dose | ||
| 0 Gy | [reference] | - |
| 0-4 Gy | 2.02 (0. 17-5.75) | 0.856 |
| > 4 Gy | 3.42 (1.29-9.03)∗ | 0.013∗ |
Abbreviations: COVID-19 = Coronavirus Disease 2019; RT = radiation therapy.
∗
Statistical significance at the 5% level.